Ozempic for Heart Failure: Off-Label Dosing Protocol, Evidence, and Clinical Guidance

What Ozempic Is Approved For (and What It Is Not)

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Novo Nordisk under two brand names with distinct approvals. Ozempic (semaglutide 0.5, 1.0, and 2.0 mg subcutaneous injection) carries FDA approval exclusively for type 2 diabetes mellitus as an adjunct to diet and exercise. Wegovy (semaglutide 2.4 mg) holds a separate approval for chronic weight management in adults with BMI of 30 or above, or BMI of 27 or above with at least one weight-related comorbidity, and received a cardiovascular risk reduction indication in March 2024 based on the SELECT trial.

Heart failure is not an FDA-approved indication for either product. This distinction matters. When clinicians prescribe Ozempic for a patient whose primary concern is heart failure, they are doing so off-label. Off-label prescribing is legal and common in medicine, but it shifts the evidentiary burden onto the prescriber. The American Heart Association has acknowledged the cardiovascular benefits of GLP-1 receptor agonists in patients with type 2 diabetes and established atherosclerotic disease, but has not issued a formal recommendation for semaglutide in heart failure management.

The Case for Semaglutide in Heart Failure: What the Trials Show

Two large clinical trials provide the foundation for off-label interest. The evidence is strongest for heart failure with preserved ejection fraction (HFpEF) in patients who also have obesity.

STEP-HFpEF (N=529), published in the New England Journal of Medicine in August 2023, randomized patients with HFpEF (ejection fraction of 45% or above) and BMI of 30 or above to semaglutide 2.4 mg weekly or placebo. At 52 weeks, semaglutide produced a 7.8-point greater improvement in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) compared to placebo (95% CI: 4.8-10.9, P<0.001). Patients on semaglutide lost a mean 13.3% of body weight versus 2.6% with placebo. The 6-minute walk distance improved by 21.5 meters more in the semaglutide group [1].

STEP-HFpEF DM (N=616) extended these findings to patients who had both HFpEF and type 2 diabetes. Results published in NEJM in March 2024 confirmed a 9.6-point improvement in KCCQ-CSS with semaglutide 2.4 mg versus placebo at 52 weeks, along with a 6.4% greater reduction in body weight [2].

SELECT (N=17,604), the largest cardiovascular outcomes trial for semaglutide, enrolled patients with established atherosclerotic cardiovascular disease and BMI of 27 or above but without diabetes. Published in NEJM in November 2023, SELECT demonstrated a 20% reduction in major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) with semaglutide 2.4 mg versus placebo over a median follow-up of 39.8 months (HR 0.80 to 95% CI: 0.72-0.90, P<0.001) [3]. A prespecified heart failure subanalysis showed a 18% relative reduction in composite heart failure events.

Dr. Mikhail Kosiborod, lead investigator of the STEP-HFpEF program and Director of Cardiometabolic Research at Saint Luke's Mid America Heart Institute, stated: "The magnitude of symptom improvement with semaglutide in HFpEF is unlike anything we've seen with prior pharmacologic therapies for this condition. The clinical significance of a nearly 8-point improvement in KCCQ is considerable."

Why HFpEF Specifically (and Not HFrEF)

The biology matters here. HFpEF accounts for roughly half of all heart failure cases in the United States, and obesity is both a risk factor and a disease modifier. Excess adiposity increases plasma volume, promotes systemic inflammation, raises left ventricular filling pressures, and worsens exercise intolerance. Semaglutide addresses several of these mechanisms simultaneously: it reduces body weight, decreases visceral fat, lowers inflammatory biomarkers (C-reactive protein dropped 39% in STEP-HFpEF), and may have direct cardiac effects through GLP-1 receptors in the atria [4].

Heart failure with reduced ejection fraction (HFrEF) is a different disease. No large trial has tested semaglutide in patients with ejection fraction below 40%. The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure recommends four foundational drug classes for HFrEF (beta-blockers, RAAS inhibitors, mineralocorticoid receptor antagonists, and SGLT2 inhibitors), and GLP-1 receptor agonists are not among them. Earlier, smaller studies of liraglutide in HFrEF (FIGHT trial, N=300) showed no benefit and a possible signal of harm, which has appropriately cooled enthusiasm for GLP-1 agonists in this population [5].

Prescribing semaglutide off-label for HFrEF has no supporting evidence. Clinicians should restrict off-label consideration to HFpEF patients with concurrent obesity.

Off-Label Dosing Protocol: How Clinicians Are Approaching It

No consensus guideline exists for dosing Ozempic in heart failure. The protocol below reflects the approach used in published trials and adapted by cardiometabolic specialists for clinical practice. It is not an endorsement of off-label use.

Starting dose: 0.25 mg subcutaneously once weekly for 4 weeks. This is a tolerability-building phase, not a therapeutic dose. Most GI side effects (nausea, vomiting, diarrhea) emerge during early titration.

Titration steps:

• Week 5: increase to 0.5 mg weekly
• Week 9: increase to 1.0 mg weekly (this is the maximum Ozempic dose covered under the diabetes indication)
• Week 13: if targeting the 2.4 mg dose studied in STEP-HFpEF, the patient would need to switch to Wegovy, as Ozempic's maximum approved dose is 2.0 mg

Dose ceiling considerations: The STEP-HFpEF trials used semaglutide 2.4 mg (the Wegovy formulation). Ozempic tops out at 2.0 mg. Whether the 0.4 mg difference is clinically meaningful for heart failure outcomes is unknown. Some clinicians maintain patients at 1.0 or 2.0 mg Ozempic if the primary goal is cardiometabolic benefit rather than maximal weight reduction.

Titration pauses: If a patient develops persistent nausea, vomiting, or diarrhea lasting more than 72 hours, hold at the current dose for an additional 4 weeks before reattempting escalation. Forced rapid titration increases dropout. In STEP-HFpEF, 10.6% of semaglutide patients discontinued due to adverse events versus 3.1% on placebo [1].

Dr. Gregg Fonarow, Chief of the Division of Cardiology at UCLA, has noted: "We do not yet have guideline-level recommendations for GLP-1 receptor agonists in heart failure. Clinicians using these agents off-label should document their rationale, obtain informed consent, and follow patients closely."

Patient Selection: Who Might Be a Candidate

Based on the STEP-HFpEF enrollment criteria, a reasonable off-label candidate would meet all of the following:

• Diagnosed HFpEF with left ventricular ejection fraction (LVEF) of 45% or above
• BMI of 30 or above (or 27 or above with obesity-related comorbidities)
• NYHA functional class II-IV symptoms despite standard heart failure management
• Stable on guideline-directed medical therapy (diuretics, SGLT2 inhibitors if indicated) for at least 30 days
• No history of medullary thyroid carcinoma or MEN2 syndrome (boxed warning for all GLP-1 receptor agonists)
• No history of pancreatitis within the prior 12 months
• eGFR of 30 mL/min/1.73m² or above

Patients who should not receive off-label semaglutide for heart failure include those with HFrEF (EF below 40%), active or recent pancreatitis, personal or family history of medullary thyroid cancer, or those currently using another GLP-1 receptor agonist. The FDA prescribing information for Ozempic lists a boxed warning regarding thyroid C-cell tumors observed in rodent studies [6].

Monitoring and Follow-Up While on Off-Label Semaglutide

Heart failure patients on off-label semaglutide require structured follow-up that goes beyond standard diabetes monitoring.

Every 4 weeks during titration:

• Body weight (target: steady loss of 0.5-1.0 kg per week; excessive rapid weight loss may indicate dehydration or diuretic interaction)
• GI symptom assessment
• Blood pressure and heart rate
• Diuretic dose adjustment (weight loss reduces volume overload, and patients may need lower loop diuretic doses)

Every 3 months once at stable dose:

• KCCQ symptom score (the same patient-reported outcome used in STEP-HFpEF; a 5-point change is clinically meaningful)
• HbA1c if the patient has concurrent diabetes
• Basic metabolic panel including renal function (eGFR, serum creatinine)
• NT-proBNP or BNP (natriuretic peptide trends help track volume status and cardiac wall stress)

Every 6-12 months:

• Echocardiogram to reassess ejection fraction and diastolic function
• 6-minute walk test if feasible
• Reassessment of whether continued off-label therapy is warranted

One interaction clinicians commonly overlook is the effect of GLP-1 agonists on gastric emptying. Semaglutide slows gastric emptying, which can alter the absorption of oral heart failure medications. The FDA has noted that while clinically significant pharmacokinetic interactions have not been observed with semaglutide in formal studies, individual patients on narrow-therapeutic-index drugs (like digoxin or warfarin) should be monitored more closely [6].

Insurance, Cost, and Access Barriers

Off-label prescribing creates insurance friction. Most commercial payers cover Ozempic for type 2 diabetes but deny claims when the documented indication is heart failure. Without a diabetes diagnosis, patients may face the full cash price, which ranges from $900 to $1,200 per month depending on pharmacy and dose.

Some clinicians manage this by documenting the concurrent diabetes or prediabetes indication when it exists. A 2023 analysis published in Diabetes Care found that approximately 40-50% of patients with HFpEF and obesity also carry a diagnosis of type 2 diabetes, making on-label prescribing possible for a subset of patients who might benefit from the cardiac effects [7].

For patients without diabetes who want access, manufacturer savings programs and specialty pharmacy options exist but rarely eliminate cost entirely. Novo Nordisk's patient assistance program may cover eligible uninsured or underinsured patients, but it requires documentation of financial need.

Prior authorization remains a frequent barrier. The average turnaround for Ozempic prior authorization is 5-14 business days, and denial rates for off-label indications exceed 60% at most large insurers based on published claims analyses.

How Semaglutide Compares to SGLT2 Inhibitors in HFpEF

SGLT2 inhibitors (empagliflozin, dapagliflozin) received FDA approval for heart failure before semaglutide generated HFpEF data, and they remain the first-line pharmacologic addition for HFpEF based on the EMPEROR-Preserved (N=5,988) and DELIVER (N=6,263) trials [8][9].

A head-to-head comparison does not exist. The mechanisms differ. SGLT2 inhibitors produce modest weight loss (2-3 kg), reduce preload through natriuresis, and lower heart failure hospitalizations. Semaglutide produces substantial weight loss (10-15%), improves symptoms and functional capacity, and reduces systemic inflammation. They are not mutually exclusive.

In STEP-HFpEF, approximately 30% of enrolled patients were taking SGLT2 inhibitors at baseline, and the benefit of semaglutide was consistent regardless of SGLT2 inhibitor use. This suggests the two drug classes may be additive for HFpEF patients with obesity, though a formal combination trial has not been completed.

The practical hierarchy for most cardiologists: optimize diuretics first, add an SGLT2 inhibitor with guideline-level evidence, then consider semaglutide off-label for patients who remain symptomatic and have BMI of 30 or above.

Ongoing Trials and the Regulatory Path Forward

The evidence base for semaglutide in heart failure is growing. Several trials are active or recently completed.

SELECT-Heart Failure is evaluating the heart failure subpopulation from SELECT for detailed outcomes. Results are expected in 2026.

STEP-HFpEF PRESERVE is a phase 3 trial investigating whether semaglutide 2.4 mg reduces heart failure hospitalizations and cardiovascular death in HFpEF patients with obesity. If positive, this trial could support a supplemental new drug application (sNDA) for a heart failure indication.

Novo Nordisk has publicly stated its intention to pursue a heart failure indication based on the combined STEP-HFpEF evidence package, though no formal sNDA has been filed as of May 2026.

Until an FDA-approved indication exists, off-label use will remain a clinical judgment call. The Endocrine Society's 2024 clinical practice guideline on pharmacologic treatment of obesity does not specifically address heart failure dosing but supports GLP-1 receptor agonist use in patients with obesity-related cardiovascular comorbidities [10].

Safety Signals Specific to Heart Failure Patients

Heart failure patients may be more vulnerable to certain semaglutide side effects than the general population.

Volume depletion: GI side effects (nausea, vomiting, diarrhea) combined with concurrent diuretic use increase the risk of dehydration, hypotension, and acute kidney injury. In STEP-HFpEF, serious adverse events occurred in 18.4% of semaglutide patients versus 26.7% of placebo patients, suggesting that semaglutide did not increase overall serious events, but individual cases of renal impairment were reported [1].

Reduced caloric intake and sarcopenia: Patients with advanced heart failure already face cardiac cachexia risk. Significant appetite suppression from semaglutide could worsen muscle mass loss. Body composition data from STEP-HFpEF showed that approximately 40% of weight lost was lean mass. Resistance exercise and adequate protein intake (1.2-1.5 g/kg/day) should be recommended for all heart failure patients on GLP-1 agonist therapy.

Arrhythmia: GLP-1 receptor agonists increase heart rate by 2-4 beats per minute on average. For patients with HFpEF and concurrent atrial fibrillation (which affects 30-50% of HFpEF patients), this effect warrants monitoring but has not been associated with increased arrhythmia events in trials.

Patients on Ozempic for heart failure should have a cardiologist involved in their care, not just an endocrinologist or primary care physician managing the prescription alone.